Overview

Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis

Status:
NOT_YET_RECRUITING

Trial end date:
2028-11-15

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at high risk of progression.

Phase:

PHASE3

Details

Lead Sponsor:

University Hospital, Tours

Treatments:

Rituximab